21st February 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Submit Data on Safety of Ropivacaine: CDSCO Asks Cipla

The drug major presented the report of the phase III trial of the Ropivacaine hydrochloride monohydrate solution for infusion at 2 milligram/millilitre before the SEC of Central Drug Standard Control Organization.

Bharat Biotech's Vaccine to be Evaluated as Covid-19 Vaccine Candidate in USA as FDA Removes Clinical Hold

Covaxin is an investigational vaccine candidate product in the United States of America.

Nigeria to Receive Vaccine Production Facility

Nigeria, Egypt, Kenya, Nigeria, Senegal, South Africa, and Tunisia have been chosen as the first six African countries that will get the technology needed to make mRNA-based vaccines.

Novavax first and second shots available for Mildura and Red Cliffs

Around 55.2% of Victorians over 18 have had three doses of a Covid vaccine.

FDA Allows Export of AstraZeneca's Vaccine

According to the American drug regulator, drugmaker’s vaccines made at Emergent BioSolutions plant are good to ship outside the US.

Inhaled drug is essential for at-home Covid treatment

United Pharm has developed incrementally modified drugs and is planning to launch inhaled Covid treatment.

FDA considering second Covid booster dose: Report

US drug regulator has been reviewing data to approve second booster shots of vaccines from Pfizer and BioNTech and Moderna.

Clinical Trials of ArCov Cancelled In Nepal

Vaccinemaker had partnered with Deurali-Janta Pharma to conduct phase 3 clinical trials in Nepal.

Livzon Pharma's Covid vaccine as a booster dose presents efficacy against omicron infection

The phase 3 clinical trial focuses to examine the efficacy, safety and immunogenicity of V-01 as a booster dose in adults above 18 after they have received two shots of inactivated vaccines.

More booster doses are on the way

The Commonwealth of the Northern Mariana Islands community can expect another phase of booster doses, as per the Commonwealth Healthcare Corporation.